gdc
FDA Approvals, News & UpdatesNewsworthy

Actemra First Treatment Approved for CAR T-Cell–Induced Cytokine-Release Syndrome

December 2017 Vol 3 No 6

On August 30, 2017, in association with the approval of the first CAR T-cell therapy (Kymriah), the FDA approved a new use for Actemra (tocilizumab; from Genentech), a humanized IL-6 receptor antagonist, for CAR T-cell–induced severe or life-threatening cytokine-release syndrome in patients older than 2. Cytokine-release syndrome can be caused by immune-cell therapy, such as CAR T-cell therapy.

This approval was based on a clinical trial showing the benefits of Actemra in patients with cytokine-release syndrome. Overall, 69% of patients had a response to Actemra within 14 days of treatment, meaning that the cytokine-release syndrome was resolved.

Serious side effects with Actemra include risk of serious infections and certain cancers, tears in the stomach, thrombocytopenia, neutropenia, hepatitis B infection, serious allergic reactions, and central nervous system problems.

Share this:

Recommended For You
Breast CancerFDA Approvals, News & Updates
FDA Approved Margenza for Patients with Metastatic HER2-Positive Breast Cancer
In December 2020, the FDA approved Margenza (margetuximab-cmkb), a new targeted therapy, for the treatment of patients with metastatic HER2-positive breast cancer, representing an important new option for patients with this type of breast cancer that continues to progress despite different treatments.
FDA Approvals, News & UpdatesLung Cancer
FDA Approves Tepmetko, New Targeted Therapy, for Patients with Metastatic Lung Cancer and MET Exon 14 Alterations
In February 2021, the FDA approved Tepmetko (tepotinib), a new oral targeted therapy, for the treatment of all adults with metastatic non–small-cell lung cancer and MET exon 14 alterations. Tepmetko is the first MET inhibitor that has been approved by the FDA.
FDA Approvals, News & UpdatesLung Cancer
Tagrisso Approved as Adjuvant Therapy for Patients with Lung Cancer and EGFR Mutations
In December 2020, the FDA approved Tagrisso (osimertinib) for adjuvant therapy (continued therapy to prevent cancer recurrence) after surgical removal of the tumor, in patients with non–small-cell lung cancer and EGFR exon 19 deletions or exon 21 L858R mutations. Tagrisso was previously approved for the treatment of other types of lung cancer.
FDA Approvals, News & UpdatesProstate Cancer
Orgovyx First FDA-Approved Oral Hormone Therapy for Patients with Advanced Prostate Cancer
In December 2020, the FDA approved Orgovyx (relugolix), as the first oral hormone therapy for the treatment of men with advanced prostate cancer. This new drug may eliminate the need to visit the clinic for treatment, helping patients with cancer avoid unnecessary exposure during the pandemic.
Last modified: January 2, 2018

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country